• The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease 

      Brakedal, Brage; Dölle, Christian; Riemer, Frank; Ma, Yilong; Nido, Gonzalo Sanchez; Skeie, Geir Olve; Craven, Alexander R.; Schwarzlmüller, Thomas; Brekke, Njål; Diab, Joseph; Sverkeli, Lars Jansen; Skjeie, Vivian; Varhaug, Kristin Nielsen; Tysnes, Ole-Bjørn; Peng, Shichun; Haugarvoll, Kristoffer; Ziegler, Mathias; Grüner, Renate; Eidelberg, David; Tzoulis, Charalampos (Journal article; Peer reviewed, 2022)
      We conducted a double-blinded phase I clinical trial to establish whether nicotinamide adenine dinucleotide (NAD) replenishment therapy, via oral intake of nicotinamide riboside (NR), is safe, augments cerebral NAD levels, ...
    • A regulatory variant at 3q21.1 confers an increased pleiotropic risk for hyperglycemia and altered bone mineral density 

      Sinnott-Armstrong, Nicholas A; Sousa, Isabel S.; Laber, Samantha; Rendina-Ruedy, Elizabeth; Dankel, Simon N; Ferreira, Teresa; Mellgren, Gunnar; Karasik, David; Rivas, Manuel A.; Pritchard, Jonathan; Guntur, Anyonya R.; Cox, Roger D.; Lindgren, Cecilia M.; Hauner, Hans; Sallari, Richard C; Rosen, Clifford J.; Hsu, Yi-Hsiang; Lander, Eric S.; Kiel, Douglas P.; Claussnitzer, Melina (Journal article; Peer reviewed, 2021)
      Skeletal and glycemic traits have shared etiology, but the underlying genetic factors remain largely unknown. To identify genetic loci that may have pleiotropic effects, we studied Genome-wide association studies (GWASs) ...